| __timestamp | Alkermes plc | Amicus Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7753000 | 47624000 |
| Thursday, January 1, 2015 | 4019000 | 76943000 |
| Friday, January 1, 2016 | 2301000 | 104793000 |
| Sunday, January 1, 2017 | 7232000 | 149310000 |
| Monday, January 1, 2018 | 68895000 | 270902000 |
| Tuesday, January 1, 2019 | 52816000 | 286378000 |
| Wednesday, January 1, 2020 | 1946000 | 308443000 |
| Friday, January 1, 2021 | 1020000 | 272049000 |
| Saturday, January 1, 2022 | 393842000 | 276677000 |
| Sunday, January 1, 2023 | 270806000 | 152381000 |
| Monday, January 1, 2024 | 245326000 |
Cracking the code
In the ever-evolving landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Amicus Therapeutics, Inc. has consistently outpaced Alkermes plc in R&D investment. From 2014 to 2023, Amicus Therapeutics increased its R&D spending by approximately 220%, peaking in 2020 with a remarkable 308 million dollars. In contrast, Alkermes plc's R&D expenditure saw a significant surge in 2022, reaching nearly 394 million dollars, a dramatic increase from its 2014 spending. This trend highlights Amicus Therapeutics' steady dedication to innovation, while Alkermes plc's recent spike suggests a strategic pivot towards more aggressive R&D investment. As the biotech industry continues to grow, these spending patterns may offer insights into each company's future trajectory and potential breakthroughs.
Research and Development: Comparing Key Metrics for Eli Lilly and Company and Amicus Therapeutics, Inc.
Research and Development: Comparing Key Metrics for AbbVie Inc. and Alkermes plc
R&D Spending Showdown: United Therapeutics Corporation vs Alkermes plc
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Alkermes plc
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Amicus Therapeutics, Inc.
R&D Insights: How Exelixis, Inc. and Amicus Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: Alkermes plc vs Viridian Therapeutics, Inc.
Research and Development Investment: Alkermes plc vs MiMedx Group, Inc.
Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
R&D Spending Showdown: Perrigo Company plc vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Geron Corporation
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Galapagos NV